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 Mitochondrial gene collection and used omics datasets
 Meta-analyses of GWAS/Exome data and transcriptomic data from
blood and brain (comparison to protein expression & qPCR data)
 Pathway and causal reasoning analysis of mitochondrial alterations
 Summary
2Updated collection of mitochondrial genes
 Collect current genes from mitochondrial localization databases MitoCarta 2.0, 
IMPI (2016/2), HMPDb and MitoPhenome
 Add genes from Gene Ontology term “Mitochondrion“
 Convert identifiers to standard HGNC gene symbols
 Retain origin annotations to enable post-filtering of likely false-positives
3Transcriptomics datasets (Brain)
2x U133A3 datasets: PD (6), control(5); PD (8), control (9)SN, post mortem
B. Zheng et al., Sci Transl Med, 
2010
U133APD (29), control (18)SN + frontal gyrus, post 
mortem
L. B. Moran et al., Neurogenetics, 
2006 




PD (16), control (9)
PD (40), control (53)
Conditions
SN, post mortem
multiple brain regions, post 
mortem 
Cell type / stage
T. G. Lesnick et al., PloS Genet, 
2007 
Y. Zhang et al., Am J Med Genet B 
Neuropsychiatr Genet, 2005 
Study
U133 Plus 2.0PD (10), control (8) SN, post mortemB. Zheng et al., Sci Transl Med, 2010
U133APD (10), control (9)SN, post mortemF. Simunovic et al., Brain, 2009
Affymetrix chipConditionsCell type / stageStudy
Datasets obtained using laser-capture microdissection (LCM):
Datasets obtained without LCM:
 only samples from the substantia nigra (SN) are used for statistical analysis
 LCM and non-LCM datasets displayed significant correlations and were thus both used for meta-analyses
4Sporadic/idiopathic PD :
LRRK2 and Parkin patients:
Transcriptomics datasets (Blood)
Affy U133A 2.0PD* (40), control (19)Whole blood, mRNACalligaris et al., 2015
Affy U133A 2.0 PD (50), control (50)Whole blood, mRNAGENEPARK
Affy U133APD (50), control (21), other 
neurodeg. disorders (33)Whole blood, mRNA
C.  R. Scherzer et al., PNAS, 
2011
ABI SOLiD 3.0, 
RNAseqPD (3), control (3)Leukocytes, mRNA
L. Soreq et al., PLoS Comp. Biol., 
2014
Affy U133A 2.0PD* (50), control (50) Whole blood, mRNADeNoPa
PlatformConditions (*drug-naive)Cell type, targetStudy
NanoString 
nCounterLRRK2 (34), control (32)Whole blood, mRNAChikina et al., 2014 (GSE62469)
Affy HG U219LRRK2 (40), control (23)Whole blood, mRNAMEFOPA






Quad beadchipPD (772), control (2024)LANDSCAPE (Dutch cohort)
NeuroX chipPD (383), SWEDD (58), control (178)PPMI
Multiple Illumina GWAS 
platformsPD (13708), control (95282)
Nalls et al., Nat. Genet., 2014
(pre-processed data from 15 independent 
GWAS datasets of European descent)
NeuroX chipPD (1298), control (883)TREND
PlatformConditionsStudy
IlluminaPD (391), SWEDD (60), control (178)PPMI
PlatformConditionsStudy
6Mitochondrial genes in the meta-analysis of GWAS data
Determine mitochondrial genes containing SNPs with putative PD associations 
from the meta-analysis of GWAS datasets (significance threshold: p < 1E-05) 
0.708granulinGRN
0.826Casein Kinase 2 BetaCSNK2B
0.887GRAM Domain Containing 4GRAMD4‡












solute carrier family 44 (choline transporter), member 1SLC44A1
cell cycle and apoptosis regulator 2CCAR2
valyl-tRNA synthetaseVARS
coiled-coil-helix-coiled-coil-helix domain containing 5CHCHD5
NADH dehydrogenase (ubiquinone) complex I,  assembly factor 2NDUFAF2
pterin-4 alpha-carbinolamine dehydratase/dimerization cofactor of 
hepatocyte nuclear factor 1 alpha (TCF1) 2
PCBD2
spermatogenesis associated 19SPATA19
mitochondrial assembly of ribosomal large subunit 1MALSU1
branched chain ketoacid dehydrogenase kinaseBCKDK*†
methylcrotonoyl-CoA carboxylase 1 (alpha)MCCC1*†
DescriptionGene Symbol
* previously shown to contain genome-wide significant SNPs, Nalls et al., 2014
Differentially expressed in transcriptomics meta-analysis: †whole-blood, ‡brain
7Mitochondrial genes in the analysis of Exome seq. data
Apply multiple variant association tests to find case/control differences in 
mitochondrial genes  limited power: need to use high p-value cut-off (p < 0.01)
MRPL53, SIRT3, (not in MitoCarta: YWHAH†)VT test
MRPL53, (not in MitoCarta: YWHAH†)UNIQ test
SIRT3, ATAD3B, ATP5J, BNIP3, CMC1, CMPK2, DIABLO‡, FASTKD2, GRSF1, LAMC1, LAP3, 
LETM1, LYRM1, LYRM9‡, MFN1, MRPS11‡, NDUFA9‡, PMPCB, PYCR1, RECQL4, SDHAF2, 
SETD9, TRMU (not in MitoCarta: ATP6V1E1, DAO, ERBB4‡, GLUL, GLYATL3, GSK3B, HSD3B2, 
KRT71, LRRC24, MAATS1, MARCKS, NPC1, PI4K2A‡, RAD51C)
SKAT test
ATAD3B, ATP5J, BNIP3, CMC1, CMPK2, DIABLO‡, FASTKD2, GRSF1, LAMC1, LAP3, LETM1, 
LYRM1, LYRM9‡, MFN1, MRPS11‡, NDUFA9‡, PMPCB, PYCR1, RECQL4, SDHAF2, SETD9, 
TRMU (not in MitoCarta: ATP6V1E1, DAO, ERBB4‡, GLUL, GLYATL3, GSK3B, HSD3B2, KRT71, 
LRRC24, MAATS1, MARCKS, NPC1, PI4K2A, RAD51C)
SUMSTAT test
MRPL53, (not in MitoCarta: YWHAH†)FRQWT test
SIRT3, ATAD3B, ATP5J, BNIP3, CMC1, CMPK2, DIABLO‡, FASTKD2, GRSF1, LAMC1, LAP3, 
LETM1, LYRM1, LYRM9‡, MFN1, MRPS11‡, NDUFA9‡, PMPCB, PYCR1, RECQL4, SDHAF2, 
SETD9, TRMU, (not in MitoCarta: ATP6V1E1, DAO, ERBB4‡, GLUL, GLYATL3, GSK3B, HSD3B2, 
KRT71, LRRC24, MAATS1, MARCKS, NPC1, PI4K2A‡, RAD51C)
C-alpha test
MRPL53, SIRT3, (not in MitoCarta: YWHAH†)Burden test
Candidate Genes (identified at least 3 times across different tests)Statistic
Genes identified at least 4 times are highlighted in matching colors
Differentially expressed in transcriptomics meta-analysis: †whole-blood, ‡brain 
8Correlation between mitochondrial changes across studies
• Significant correlations of 
PD vs. control log. fold 
changes of mitochondrial 
genes across transcript-
omics studies for the 
same tissue/body fluid
• Correlations between 
brain (substantia nigra)
datasets higher than 
between whole-blood 
datasets
• Correlations between 








9Top-ranked genes from brain/blood meta-analysis
 Determine genes with significant differential expression in the meta-analyses 
(Marot et al., 2011) for brain (substantia nigra) and whole-blood (FDR < 0.05)
 All genes have a MitoCarta FDR-score ≤ 0.03 for mitochondrial localization
0.019-4.00.001-4.1prenyl (decaprenyl) diphosphate 
synthase, subunit 2PDSS2
0.038-3.40.025-2.8neugrin, neurite outgrowth associatedNGRN
0.041-3.30.004-3.5leucine rich pentatricopeptide repeat 
containingLRPPRC
0.041-3.40.012-3.1transcription factor B1, mitochondrialTFB1M
0.041-3.2<0.001-4.4solute carrier family 25 member 17SLC25A17
0.023-3.80.015-3.0nicotinamide nucleotide transhydrogenaseNNT
0.022-3.80.013-3.1methylcrotonoyl-CoA carboxylase 2MCCC2












Relevant information in the literature for top-ranked genes
1) AFG3L2: Subunit of a metalloprotease involved in maintenance of the mitochondrial 
proteome; loss of AFG3L2 causes complex I deficiency and increased sensitivity to 
oxidative stress in hereditary spastic paraplegia (Atorino & Casari, 2003)
2) MCCC2: Subunit in carboxylase protein complex with MCCC1, a gene with a known 
PD risk factor mutation (rs12637471, PDGENE Meta-P: 5.4E-22, Nalls et al., 2014)
3) NTT: Encodes integral protein of inner mitochondrial membrane, couples hydride 
transfer between NAD(H) and NADP(+) to proton translocation across the membrane. 
4) TFB1M: Encodes a dimethyltransferase that methylates the conserved stem loop of 
mitochondrial 12S rRNA (necessary for mtDNA transcription, Falkenberg et al., 2002)
5) LRPPRC: transcriptional regulator of both nuclear and mitochondrial genes
6) PDSS2: synthesizes prenyl side-chain of coenzyme Q10 (CoQ) in the respiratory 
chain; defects in this gene are a cause of CoQ deficiency (Lopez et al., 2012)
11
qPCR validation and check for multimodal distribution in PD
Validate top-ranked differentially expressed genes from the meta-analysis of 
microarray datasets for whole-blood samples using qRT-PCR (11 patients and 11 
age- and gender-matched controls  validated qualitative changes for 26 out of 36 










Normalized gene expression in PD
Dip test:  p = 0.14
MRPL42
12
Alterations in mitochondrial processes and complexes
Identify mitochondrial processes and complexes (Gene Ontology, CORUM) with 
differential median expression in whole-blood transcriptomics data from IPD 
patients & controls (only processes with min. of 10 mapped genes): 
7.0E-03-0.28inner mitochondrial membrane protein complex
7.0E-03-0.26protein targeting to mitochondrion
5.7E-03-0.19mitochondrial envelope




7.2E-04-0.46establishment of mitochondrion localization
2.4E-05-0.78mitochondrial calcium ion homeostasis
1.1E-05-0.58mitochondrion morphogenesis
2.0E-09-0.95regulation of mitochondrial translation
FDRlogFCMitochondrial process / complex / GO term
13
Causal reasoning analysis of mitochondrial transcriptomics
Use causal reasoning analysis (Chindelevitch, 2012) of differentially expressed 
mitochondrial genes from the blood transcriptomics meta-analysis to identify 
alterations in regulators that can explain the observed downstream changes.
under-expressed in PD over-expressed in PD consistent inconsistent
14
Summary
• Joint analysis of GWAS/exome and transcriptomics data identifies mitochondrial 
genes with putative PD-associated SNPs and significant alterations in the 
transcriptomics meta-analyses
• Mitochondrial genes with shared expression alterations in meta-analyses for blood 
and brain transcriptomics data were determined and compared to representative 
qPCR and protein expression measurements to find the most robust changes
• Mitochondrial processes with differential median gene expression were ranked and 
a causal reasoning analysis identified changes in NRF1 expression as a potential 
key regulatory event behind downstream mitochondrial alterations in PD
15
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